Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
- Incoming Industry Veteran to Lead Clinical Supply Chain Operations and Architect the Build Out of the Anticipated Commercial Supply Chain
NEW YORK, Oct. 31, 2016 -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Bernie Cunningham, Ph.D, to the position of Executive Director of Clinical Supply Chain and Logistics, and CMC Project Management. This new hire will report to Kaushik J. Dave, Ph.D, Actinium’s Chief Executive Officer, as a keystone hire in the Company’s growing Supply Chain Team.
“We are enormously gratified to welcome Dr. Cunningham to the Actinium Pharmaceuticals team,” said Kaushik J. Dave, Ph.D, Actinium’s Chief Executive Officer. “The hiring of such a skilled and experienced executive shortly after onboarding Dr. Maria Nunes and Ms. Laura Chen reinforces my confidence in our ability to attract requisite talent as we continue to perfect pre-commercialization capabilities for our phase 2 and phase 3 programs, increase readiness for commercialization and also prepare for pipeline expansion.”
Dr. Cunningham will have a leadership role, responsible for further establishment of the Company’s supply chain infrastructure and related distribution strategies, all of which will provide critical support to clinical operations both in the United States and outside the United States. She will also oversee Actinium’s relationships with external contract manufacturing organizations and contract testing labs for all clinical trial material supplies. Dr. Cunningham has approximately thirty years of experience in the pharmaceutical and biotechnology industries, with a dedication to supply chain and project management within the last fifteen years. As a Certified Project Management Professional she brings extensive experience in development of investigational medical products in various physical forms. She led teams and directed multiple projects in manufacturing, supply chain and QA/QC at companies including Mesoblast and OSI Pharmaceuticals. She began her professional career as a Research Scientist and Principal Investigator at OSI Pharmaceuticals, and most recently had the title of Director, Project Management – Manufacturing and QA at Mesoblast. Dr. Cunningham holds a Ph.D. in Medicinal Chemistry from University of Aston in Birmingham, U.K., as well as a BSc (Hons) from University of Aston, and has written a number of papers published in peer-reviewed pharmacology journals.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact: Steve O'Loughlin Vice President, Finance and Corporate Development Actinium Pharmaceuticals, Inc. [email protected]
